Last reviewed · How we verify
Malathion gel 0.5%
Malathion is an organophosphate insecticide that inhibits acetylcholinesterase, causing accumulation of acetylcholine and paralysis of parasites.
Malathion is an organophosphate insecticide that inhibits acetylcholinesterase, causing accumulation of acetylcholine and paralysis of parasites. Used for Head lice infestation (pediculosis capitis), Scabies (Sarcoptes scabiei infestation).
At a glance
| Generic name | Malathion gel 0.5% |
|---|---|
| Also known as | MALG |
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Drug class | Organophosphate insecticide |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Malathion works by irreversibly inhibiting the enzyme acetylcholinesterase in insects and parasites, leading to excessive acetylcholine accumulation at nerve synapses and neuromuscular junctions. This results in overstimulation, paralysis, and death of the target organisms. The gel formulation allows topical application for localized treatment of parasitic infestations.
Approved indications
- Head lice infestation (pediculosis capitis)
- Scabies (Sarcoptes scabiei infestation)
Common side effects
- Scalp irritation
- Pruritus
- Erythema
- Contact dermatitis
- Burning sensation
Key clinical trials
- Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice (PHASE3)
- Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice (PHASE3)
- Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Malathion gel 0.5% CI brief — competitive landscape report
- Malathion gel 0.5% updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI